Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement

Saúl Reyes; Anthony L. Cunningham; Tomas Kalincik; Eva Kubala Havrdová; Noriko Isobe; Julia Pakpoor; Laura Airas; Reem F. Bunyan; Anneke van der Walt; Jiwon Oh; Joela Mathews; Farrah J. Mateen; Gavin Giovannoni

doi:10.1016/j.jneuroim.2021.577627

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement

Saúl Reyes, Anthony L. Cunningham, Tomas Kalincik, Eva Kubala Havrdová, Noriko Isobe, Julia Pakpoor, Laura Airas, Reem F. Bunyan, Anneke van der Walt, Jiwon Oh, Joela Mathews, Farrah J. Mateen, Gavin Giovannoni

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

In this consensus statement, we provide updated recommendations on multiple sclerosis (MS) management during the COVID-19 crisis and the post-pandemic period applicable to neurology services around the world. Statements/recommendations were generated based on available literature and the experience of 13 MS expert panelists using a modified Delphi approach online. The statements/recommendations give advice regarding implementation of telemedicine; use of disease-modifying therapies and management of MS relapses; management of people with MS at highest risk from COVID-19; management of radiological monitoring; use of remote pharmacovigilance; impact on MS research; implications for lowest income settings, and other key issues.

Original language	English (US)
Article number	577627
Journal	Journal of Neuroimmunology
Volume	357
DOIs	https://doi.org/10.1016/j.jneuroim.2021.577627
State	Published - Aug 15 2021

Keywords

COVID-19
Disease-modifying treatment
Multiple sclerosis
Pharmacovigilance
Telemedicine

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

Access to Document

10.1016/j.jneuroim.2021.577627

Cite this

Reyes, S., Cunningham, A. L., Kalincik, T., Havrdová, E. K., Isobe, N., Pakpoor, J., Airas, L., Bunyan, R. F., van der Walt, A., Oh, J., Mathews, J., Mateen, F. J., & Giovannoni, G. (2021). Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. Journal of Neuroimmunology, 357, Article 577627. https://doi.org/10.1016/j.jneuroim.2021.577627

Reyes, S, Cunningham, AL, Kalincik, T, Havrdová, EK, Isobe, N, Pakpoor, J, Airas, L, Bunyan, RF, van der Walt, A, Oh, J, Mathews, J, Mateen, FJ & Giovannoni, G 2021, 'Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement', Journal of Neuroimmunology, vol. 357, 577627. https://doi.org/10.1016/j.jneuroim.2021.577627

@article{08b98b64f38c48e39fd8f155dc4b44fa,

title = "Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement",

abstract = "In this consensus statement, we provide updated recommendations on multiple sclerosis (MS) management during the COVID-19 crisis and the post-pandemic period applicable to neurology services around the world. Statements/recommendations were generated based on available literature and the experience of 13 MS expert panelists using a modified Delphi approach online. The statements/recommendations give advice regarding implementation of telemedicine; use of disease-modifying therapies and management of MS relapses; management of people with MS at highest risk from COVID-19; management of radiological monitoring; use of remote pharmacovigilance; impact on MS research; implications for lowest income settings, and other key issues.",

keywords = "COVID-19, Disease-modifying treatment, Multiple sclerosis, Pharmacovigilance, Telemedicine",

author = "Sa{\'u}l Reyes and Cunningham, {Anthony L.} and Tomas Kalincik and Havrdov{\'a}, {Eva Kubala} and Noriko Isobe and Julia Pakpoor and Laura Airas and Bunyan, {Reem F.} and {van der Walt}, Anneke and Jiwon Oh and Joela Mathews and Mateen, {Farrah J.} and Gavin Giovannoni",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = aug,

day = "15",

doi = "10.1016/j.jneuroim.2021.577627",

language = "English (US)",

volume = "357",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic

T2 - An international consensus statement

AU - Reyes, Saúl

AU - Cunningham, Anthony L.

AU - Kalincik, Tomas

AU - Havrdová, Eva Kubala

AU - Isobe, Noriko

AU - Pakpoor, Julia

AU - Airas, Laura

AU - Bunyan, Reem F.

AU - van der Walt, Anneke

AU - Oh, Jiwon

AU - Mathews, Joela

AU - Mateen, Farrah J.

AU - Giovannoni, Gavin

PY - 2021/8/15

Y1 - 2021/8/15

N2 - In this consensus statement, we provide updated recommendations on multiple sclerosis (MS) management during the COVID-19 crisis and the post-pandemic period applicable to neurology services around the world. Statements/recommendations were generated based on available literature and the experience of 13 MS expert panelists using a modified Delphi approach online. The statements/recommendations give advice regarding implementation of telemedicine; use of disease-modifying therapies and management of MS relapses; management of people with MS at highest risk from COVID-19; management of radiological monitoring; use of remote pharmacovigilance; impact on MS research; implications for lowest income settings, and other key issues.

AB - In this consensus statement, we provide updated recommendations on multiple sclerosis (MS) management during the COVID-19 crisis and the post-pandemic period applicable to neurology services around the world. Statements/recommendations were generated based on available literature and the experience of 13 MS expert panelists using a modified Delphi approach online. The statements/recommendations give advice regarding implementation of telemedicine; use of disease-modifying therapies and management of MS relapses; management of people with MS at highest risk from COVID-19; management of radiological monitoring; use of remote pharmacovigilance; impact on MS research; implications for lowest income settings, and other key issues.

KW - COVID-19

KW - Disease-modifying treatment

KW - Multiple sclerosis

KW - Pharmacovigilance

KW - Telemedicine

UR - http://www.scopus.com/inward/record.url?scp=85107740699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107740699&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2021.577627

DO - 10.1016/j.jneuroim.2021.577627

M3 - Review article

C2 - 34139567

AN - SCOPUS:85107740699

SN - 0165-5728

VL - 357

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

M1 - 577627

ER -

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this